Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 4/2020

01-10-2020 | Original Article

Study of Prothrombotic Changes in Metabolic Syndrome

Authors: Jitender Mohan Khunger, Nitin Kumar, V. P. S. Punia, Monica Khunger Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2020

Login to get access

Abstract

The metabolic syndrome is a complex disorder of various metabolic risk factors in a single individual having central obesity and commonly associated with diabetes and cardiovascular diseases. The aim of our study was to study the relationship between coagulation abnormalities and metabolic syndrome. We performed a prospective cross-sectional study in a tertiary care hospital. A total of fifty cases of metabolic syndrome and fifty age & sex matched controls were selected. These two groups were investigated for Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen levels, Plasminogen Activator Inhibitor 1(PAI1) levels and Factor VIII levels. In cases with metabolic syndrome, significantly increased levels of Fibrinogen, Factor VIII and Plasminogen Activator Inhibitor1 (PAI1) were observed. PT & APTT were shorter in cases with metabolic syndrome. The coagulation parameters studied, correlated significantly with the components of metabolic syndrome. Metabolic syndrome is a hypercoagulable state and further studies are required for further evaluation of the consequences of this hypercoagulable state. There is a need for clinical trials evaluating prophylactic anticoagulation for prevention of venous thrombosis in patients with metabolic syndrome.
Literature
1.
go back to reference Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 3:433–438CrossRef Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 3:433–438CrossRef
2.
go back to reference Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469–480CrossRef Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469–480CrossRef
3.
go back to reference National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143–3421CrossRef National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106(25):3143–3421CrossRef
4.
go back to reference Mutch NJ, Wilson HM, Booth NA (2001) Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 60(3):341–347CrossRef Mutch NJ, Wilson HM, Booth NA (2001) Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 60(3):341–347CrossRef
5.
go back to reference De Pergola G, Pannacciulli N (2002) Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25(10):899–904CrossRef De Pergola G, Pannacciulli N (2002) Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25(10):899–904CrossRef
6.
go back to reference Acang N, Jalil FD (1992) Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Public Health 24(Suppl 1):263–266 Acang N, Jalil FD (1992) Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Public Health 24(Suppl 1):263–266
9.
go back to reference Fu G, Yan Y, Chen L, Zhang M et al (2018) Shortened activated partial thromboplastin time and increased superoxide dismutase levels are associated with type 2 diabetes mellitus. Ann Clin Lab Sci 48(4):469–477PubMed Fu G, Yan Y, Chen L, Zhang M et al (2018) Shortened activated partial thromboplastin time and increased superoxide dismutase levels are associated with type 2 diabetes mellitus. Ann Clin Lab Sci 48(4):469–477PubMed
11.
go back to reference Ford ES (2003) The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis. 168:351–358CrossRef Ford ES (2003) The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis. 168:351–358CrossRef
12.
go back to reference Mahendra JV, Satish Kumar D et al (2015) Plasma fibrinogen in type 2 diabetic patients with metabolic syndrome and its relation with ischemic heart disease (IHD) and retinopathy. J Clin Diagn Res. 9(1):BC18–BC21PubMedPubMedCentral Mahendra JV, Satish Kumar D et al (2015) Plasma fibrinogen in type 2 diabetic patients with metabolic syndrome and its relation with ischemic heart disease (IHD) and retinopathy. J Clin Diagn Res. 9(1):BC18–BC21PubMedPubMedCentral
13.
go back to reference Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O (1998) Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 21(4):649–654CrossRef Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O (1998) Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 21(4):649–654CrossRef
14.
go back to reference Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF et al (1995) The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 5(6):464–472CrossRef Wagenknecht LE, Mayer EJ, Rewers M, Haffner S, Selby J, Borok GM, Henkin L, Howard G, Savage PJ, Saad MF et al (1995) The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 5(6):464–472CrossRef
15.
go back to reference Garg MK, Dutta MK, Mahalle N (2012) Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome. Indian J Endocrinol Metab. 16(1):116–123CrossRef Garg MK, Dutta MK, Mahalle N (2012) Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome. Indian J Endocrinol Metab. 16(1):116–123CrossRef
16.
go back to reference Bilgili S, Celebiler AC, Dogan A, Karaca B (2008) Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocr Regul. 42(2–3):63–68PubMed Bilgili S, Celebiler AC, Dogan A, Karaca B (2008) Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocr Regul. 42(2–3):63–68PubMed
18.
go back to reference Conlan MG, Folsom AR, Finch A et al (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the atherosclerosis risk in communities (ARIC) study. Thromb Haemost 70(3):380–385CrossRef Conlan MG, Folsom AR, Finch A et al (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the atherosclerosis risk in communities (ARIC) study. Thromb Haemost 70(3):380–385CrossRef
Metadata
Title
Study of Prothrombotic Changes in Metabolic Syndrome
Authors
Jitender Mohan Khunger
Nitin Kumar
V. P. S. Punia
Monica Khunger Malhotra
Publication date
01-10-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01291-y

Other articles of this Issue 4/2020

Indian Journal of Hematology and Blood Transfusion 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine